progress my you thank joining during the to And made participants to that we It's today. update us Kimberly. you, the quarter. on Thank pleasure for have clinical our you
a data is will clinical number a nebulizer XXXX a well busy as the So year with of with new on update focus with of formulation exciting ensifentrine, formulation. as powder value-creating milestones. ongoing studies dry important a naturally Today's
unique, disease inhibitor is will quality function, increase first-in-class previously obstructive improve chronic of a reminder, both pulmonary life with that and in a properties anti-inflammatory ensifentrine with lung PDEX of reduce millions and patients or PDX or and As bronchodilator RPLXXX dual we COPD. believe symptoms
breathing improve differentiated is is dose further already maximum treatments, ensifentrine in on from truly run standard-of-care as existing have medications, able reduce of and that it believe COPD to options. out symptoms treatment We patients that
and World that in cause by predicts of or medical billion the costs the Health $XX and COPD WHO, third clinical in year, the COPD, to to rise to alone, the no treatment disease death XXXX. Organization for Xb become U.S. leading Ensifentrine life-threatening the the maintenance, will is that next is In Phase XXXX currently a of cure. progressive related globally development COPD predicted are with
despite a with over a differentiated novel-class breakthrough would being first therapy. of symptomatic large lung who standard-of-care XX with ensifentrine on to that potential believe of maximum for patients years number function be has remain the in We This the profile. bronchodilator be bronchodilator a a deteriorating
a options more are that for are time. better treatments. COPD available is at today patients These limited of patients two the severe Treatment That population. need same particularly bronchodilators of the for a innovation, urgently of types with different combination a lack
efficacy data or clinical of tolerability and results was at this we very Madrid, continue Congress Respiratory September and in and the Our Society received. to European formulation COPD dry of presented X well it support Phase ensifentrine year, powder in positive the from patients, in the inhaler study DPI
crossover or in this for and this dry dosing primary evaluating twice endpoints announced All These this tolerability novel XX lung days in data formulation function placebo-controlled DPI first powder study and were patients. efficacy randomized, secondary achieved August daily year. seven were double-blind of of in
These a primary for function. milliliter Forced in tested, are or corrected second, standard over measuring measure showed to function, milliliter baseline FEVX, XXX Volume peak which endpoint were is which lung lung of placebo improvements X,XXX X for or and dose-dependent microgram. Expiratory The a microgram, microgram, substantial improvements doses X,XXX in XXX four XXX XXX
meaningful clinically are statistically and They significant. highly
over dosing in robust in Secondary were met durability the effects of dosing This formulation. in period significant demonstrated XX interval trough endpoints average supportive the data average trial, including XX-hour hours. are on clinical of a full FEVX over together day-X, statistically FEVX ensifentrine improvements also during of and this also with twice-daily the a
safety nebulized that well profile DPI and with to tolerated with adverse an at studies in also in was similar Ensifentrine ensifentrine. observed event very formulation all comparable prior was the profile the placebo indeed doses to
has trial two-part reporting placebo-controlled of slower anticipate in part and via unfortunately Dose been dose-ranging with The moderate-to-severe this formulation, the pMDI X or and pressurized safety evaluate COPD. trial data are In and we addition design. expected mid-next year and Phase of with or year. DPI we trial double-blind randomized, a than this from next a PK Metered patients first ensifentrine in profile, Inhaler in UK Recruitment quarter the first efficacy has to data the study conducting pharmacokinetic final trial pMDI, XXXX, to a of this delivered
handheld delivered prototype asthma data DPI perhaps ensifentrine's for devices as convenient, and formulation COPD the with device powder more with support most patients these So a use their to pMDI dry medications. and potential and via be
in expand either of ensifentrine these An patients formats at valued COPD inhaler $X to potential the million availability ensifentrine We believe DPI billion the millions who estimated in last the devices. U.S. alone of such an or greatly use X.X could was use market patients market device COPD for to prefer the MDI XXXX. and year, approximately
partner the commercialization. pMDI the maximize development commercial our of value and formulation or To to further is of strategy ensifentrine, its DPI
common symptomatic patients, lung with For function U.S., medicines. despite the deteriorating market show patients research administration, of severe and a approximately available the maximum X,XXX,XXX a more of taking remain currently in that COPD is delivery payer very route especially doses our nebulized standard-of-care where
treatments severe options for in treatment few, Few these development remains and for if them. any, there new are patients
Our continue strong very to so ensifentrine support clinical of on the effect data, symptoms COPD. a of
ensifentrine nebulized its data Meeting of COPD. – the positive data excuse symptom March data from New symptoms. Annual trial This presented symptom on progressive in significant in Phase this broad In October first range with at we expanded this Orleans, COPD with March with improvements and announced assessment in year, tools me, in showed year last further obtained a CHEST our four-week Xb
Xb patients year. trial Enrollment XXX in Phase initiated October trial, this efficacy to four the of are second to and We moderate-to-severe completed this XXXX four-week in to patient plan. taken COPD six our May and safety with that this sites clinical was progressing evaluate dose-ranging ensifentrine very pleased at in trial clinical is the We in some U.S.
or tolerability Patients used levels mg evaluate mg, with is treat of a twice-daily placebo the nebulized ensifentrine including of add-on weeks. X.X X.XX inhaled four efficacy and commonly X.XXX patients to and Long-Acting X COPD. received at mg, ensifentrine The trial to four an to LAMA, nebulized or dose as dose a low for tiotropium, Antimuscarinic designed
The as in lung peak improvement as of outcome FEVX, include of measures, this measurements of life and different key as symptoms quality lung endpoint primary endpoints respiratory measured study function, by tools. well by patient-reported other function additional is
to add-on and FDA So in long-acting the additional purpose with main present is setting study this information the dose-ranging an bronchodilator. ensifentrine one of to
that on dose bronchodilator although curve We may function. lowest positive, relatively an FEVX studies the lung and response, response is flat indicate dose still have the expect dose-dependent effect so a earlier or
patients. This four-week clinical the plan symptomatic first last to Phase FDA ensifentrine thereafter earlier Phase in of conduct the second we XXXX year and Meeting an evaluate end-of-Phase following the study study half completion different patient a COPD in and completed study, XXX setting Xb for of X successfully with treatment Phase Xb complements of a maintenance program the X commence to
data the very plan a we and of trials exposure. and positive and X outcome Phase regulatory to the on conduct clinical twelve with ensifentrine two safety pivotal the preclinical month Meeting, FDA Based to-date,
and bronchodilator for label. patients COPD and conduct important only We treatment with FEVX an one using no expect in a in background could to patients endpoint the broad be studies
to Xb program We significantly expect for conduct COPD X is Phase therapy. based discussed. an in we plan studies be dual just to more payers it physicians Separately, derisked severe on study additional the market-positioning with and patients and as triple the Phase two
Phase to in year. two both start We next the expect trials regulatory X XXXX,
these in well milestones are formulation, developments into upcoming value-creating that a important the believe We and nebulized formulation. ensifentrine events regulatory as of inhaler a as handheld both in value commercial feeding directly
Piers a turn over CFO, now overview. call provide the will to financial our I to Morgan
